NYSE$DNA

Ginkgo Bioworks Holdings · Q2 2022 earnings

Q2 2022 earnings · · Investor relations

Headline financials

Total Revenue

$145M

Previous: $9.82M+1373.1%
EPS (adj)

-$16.40

Previous: -$4.00-310.0%
Capital Expenditures

-$13.2M

Previous: $24M-154.7%
Free Cash Flow

-$682M

Previous: -$107M-538.8%
Net Income

-$669M

Previous: -$107M-526.5%
Operating Income

-$647M

Previous: -$5.31M-12080.6%
Gross Profit

$80.7M

Previous: $9.82M+722.1%
Cash & Equivalents

$1.38B

Previous: $37.6K+3659715.6%
Total Assets

$1.99B

Previous: $1.73B+15.5%
Stock-Based Comp

$607M

Previous: $14.5M+4077.4%

Revenue & EPS history

Ginkgo Bioworks · Revenue · Quarterly

$145M

Q2 2022+1,373.1%vs Q2 2021
Beat estimate in 10 of 14 quarters(71%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2022

Historical avgQ2 2022

-2.5%

Avg return

Earnings day

-8.6%

Avg return

5 days after

-12.3%

Avg return

30 days after

32%

7 / 22 earnings

Positive

+25.4%

Q4 2021

Best reaction

-20.8%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+1.9%-17.5%-19.4%
Q4 2025+3.1%-28.6%-36.8%
Q3 2025-20.8%-26.0%-18.1%
Q1 2025+14.8%+28.8%+17.7%
Q4 2024-11.5%-22.2%-40.5%
Q3 2024-1.8%-27.3%+17.9%
Q2 2024-1.5%+2.6%-48.4%
Q1 2024-14.8%-3.4%-42.4%
Q4 2023-15.1%-24.3%-23.7%
Q3 2023-18.2%-16.9%-11.7%
Q2 2023-15.9%-13.9%+0.0%
Q1 2023-2.9%-3.6%+35.0%
Q4 2022-4.8%-7.5%-9.5%
Q3 2022-6.3%-23.2%-41.1%
Q2 2022+3.0%-21.5%-15.4%
Q1 2022+3.0%-1.9%-2.6%
Q4 2021+25.4%+14.8%-6.3%
Q4 2019-0.3%-0.5%-11.8%
Q3 2021+8.5%+4.3%-15.9%
Q2 2021-0.1%-0.3%+1.5%
Q1 2021+0.0%-0.2%+0.2%
Q4 2020+0.0%-0.2%+0.2%
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro